Table 4.
Genotype | Ile/Ile | Ile/Val | OR (95 % CI)a | p-Valueb |
---|---|---|---|---|
Controls | 466 | 29 | ||
Patients | ||||
Clinical stage | ||||
IA | 55 | 6 | 1.753 (0.697–4.410) | 0.2275 |
IB | 57 | 6 | 1.691 (0.673–4.250) | 0.2584 |
IIA | 53 | 6 | 1.819 (0.722–4.583) | 0.1982 |
IIB | 49 | 6 | 1.968 (0.779–4.973) | 0.1455 |
IIIA | 139 | 9 | 1.040 (0.481–2.251) | 0.9200 |
IIIB | 48 | 5 | 1.674 (0.619–4.526) | 0.3051 |
IVA | 7 | 2 | 4.591 (0.912–23.107) | 0.1006c |
IVB | 7 | 1 | 2.296 (0.273–19.300) | 0.3907c |
Histologic grade | ||||
G1 | 80 | 7 | 1.406 (0.596–3.319) | 0.4347 |
G2 | 133 | 12 | 1.450 (0.720–2.920) | 0.2958 |
G3 | 91 | 7 | 1.236 (0.525–2.908) | 0.6267 |
Histologic type | ||||
Squamous cell carcinoma | 353 | 31 | 1.407 (0.832–2.379) | 0.2003 |
Adenocarcinoma | 48 | 6 | 2.009 (0.794–5.081) | 0.1336 |
ORs for patients with histologic grade Gx and unknown histologic type of cervical cancer were not calculated
a(Ile/Val vs. Ile/Ile)
bChi square analysis
cFisher exact test
CI confidence interval, OR odds ratio